A retrospective study evaluating the outcomes of high‐dose methylprednisolone pulse therapy for 483 patients with moderate‐to‐severe alopecia areata
- 13 July 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1267-1269
Abstract
Alopecia areata (AA) is a chronic autoimmune skin disease with hair loss, which often results in a poor prognosis. Although the high-dose intravenous methylprednisolone pulse therapy (IVMP) is used for AA, predictive factors affecting efficacies of IVMP are not fully elucidated. Thus, we conducted a retrospective study reviewing IVMP for AA during January 2009 and December 2018. The study was approved by the ethical committee of the Tohoku University Graduate School of Medicine.Keywords
This publication has 7 references indexed in Scilit:
- Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patientsThe Journal of Dermatology, 2021
- Elucidation of demographic, clinical and trichoscopic features for early diagnosis of self‐healing acute diffuse and total alopeciaThe Journal of Dermatology, 2020
- Predictive factors of response to pulse methylprednisolone therapy in patients with alopecia areata: A follow‐up study of 105 Japanese patientsThe Journal of Dermatology, 2019
- A systematic review of pulse steroid therapy for alopecia areataJournal of the American Academy of Dermatology, 2016
- Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosisJournal of the American Academy of Dermatology, 2009
- Loss-of-Function Mutations in the Filaggrin Gene and Alopecia Areata: Strong Risk Factor for a Severe Course of Disease in Patients Comorbid for Atopic DiseaseJournal of Investigative Dermatology, 2007
- Acute Diffuse and Total Alopecia of the Female ScalpDermatology, 2002